期刊
JOURNAL OF INFECTIOUS DISEASES
卷 205, 期 1, 页码 152-161出版社
OXFORD UNIV PRESS INC
DOI: 10.1093/infdis/jir621
关键词
-
资金
- National Institute of Allergy and Infectious Disease [AI057992, AI063402, AI032121]
- National Institute of Child Health and Development [HD041187]
- National Cancer Institute [CA096651, CA103320, CA112431]
- National Institute of Arthritis and Musculoskeletal and Skin Diseases [AR007594]
- NewLink Genetics Inc.
Recent studies have underscored physiological and pathophysiological roles for the tryptophan-degrading enzyme indolamine 2,3-dioxygenase (IDO) in immune counterregulation. However, IDO was first recognized as an antimicrobial effector, restricting tryptophan availability to Toxoplasma gondii and other pathogens in vitro. The biological relevance of these findings came under question when infectious phenotypes were not forthcoming in IDO-deficient mice. The recent discovery of an IDO homolog, IDO-2, suggested that the issue deserved reexamination. IDO inhibition during murine toxoplasmosis led to 100% mortality, with increased parasite burdens and no evident effects on the immune response. Similar studies revealed a counterregulatory role for IDO during leishmaniasis (restraining effector immune responses and parasite clearance), and no evident role for IDO in herpes simplex virus type 1 (HSV-1) infection. Thus, IDO plays biologically important roles in the host response to diverse intracellular infections, but the dominant nature of this role-antimicrobial or immunoregulatory-is pathogen-specific.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据